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ABSTRACT
Addiction is a major public-health crisis associated with significant disability and mortality. Although
various pharmacological and behavioral treatments are currently available, the clinical efficacy of these
treatments is limited. Given this situation, there is a growing interest in finding an effective neurosurgical
treatment for addiction. First, we discuss the use of ablative surgery in treating addiction. We focus on the
rise and fall of nucleus accumbens ablation for addiction in China. Subsequently, we review recent studies
that have explored the efficacy and safety of deep-brain-stimulation treatment for addiction. We conclude
that neurosurgical procedures, particularly deep-brain stimulation, have a potentially valuable role in the
management of otherwise intractable addictive disorders. Larger well-controlled clinical trials, however, are
needed to assess clinical efficacy and safety. We end by discussing several key issues involved in this clinical
field and identifying some areas of progress.
Keywords: drug addiction, psychosurgery, ablative surgery, deep-brain stimulation, medical ethics
INTRODUCTION
Addiction is characterized by intense and sometimes
uncontrollable craving and compulsive addictive-
substance seeking, which persist despite severe and
potentially fatal consequences [1]. Even after pro-
longed abstinence, patients remain at elevated risk of
relapse, especially when cues evoke memories asso-
ciated with the addictive substance [2] or when pa-
tients are exposed to stress or craving symptoms [3].
Addiction-associated problems impose a high eco-
nomic and social burden on society, including sub-
stantial healthcare costs due to medical complica-
tions and high-risk behaviors (e.g. needle-sharing),
crime and lost work productivity [4,5]. In 2015, a
global survey showed that tobacco smoking, alcohol
and drug use were associated with 16.2% of the to-
tal disease burden in men [6]. In 2014, it was es-
timated that more than 4.9%, 3.5% and 22.5% of
the world’s adult population had an alcohol-use dis-
order, illicitly used psychoactive drugs or were ad-
dicted to tobacco products, respectively, causing an
estimated 25 783 disability-adjusted years of life lost
per 100 000 people. Moreover, substance-use disor-
ders accounted for 11% of all deaths in males and
for 6% of deaths in females [4]. The often chronic,
relapsing nature of substance-use disorders is a key
factor in contributing to their high disease burden.
Today, about 85%of addicted individuals are known
to relapse within 1 year of treatment, despite the
availability of medications approved for relapse
treatment (e.g. methadone) and various behavioral
interventions developed for relapse prevention (e.g.
Marlatt’s intervention, self-help intervention, cue
exposure therapy) [7,8]. Accordingly, the efficacy
of current behavioral and pharmaceutical interven-
tions for treating addiction is limited, which is par-
ticularly concerning given the scale of the problem.
Given this situation, there is a growing interest in
finding an effective neurosurgical treatment for se-
vere and treatment-refractory cases of substance-use
disorders.
Neurosurgery for treating psychiatric disorders
has a long and controversial history. However, psy-
chosurgery has regained momentum in the past few
decades with the advent of deep-brain stimulation
(DBS). DBS involves the delivery of electrical stim-
ulation to gray or white matter in a therapeutic ef-
fort to change pathological brain activity (Fig. 1).
C©TheAuthor(s) 2019. Published byOxfordUniversity Press on behalf of China Science Publishing&Media Ltd.This is anOpen Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original
work is properly cited.
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Figure 1. Devices for DBS and the programming system. (A) and (B) show DBS leads
implanted in the brain and connected through an extension cable to a neurostimula-
tor (impulse generator) located in the chest below the clavicle. (C) shows that a physi-
cian could program DBS using parameters including contact selection, stimulating volt-
age/current, frequency and pulse width (D).
Ablative surgery for addiction
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Figure 2. Timeline of neurosurgical-therapy development in addiction. According to
the modus operandi and time sequence, neurosurgical treatment of addiction can be
divided into two main stages. The first stage is represented by the ablative surgery
such as bilateral cingulotomy and NAc ablative surgery whereas the second stage is
represented by the DBS in various brain areas. OCD, obsessive-compulsive disorder;
NAc, nucleus accumbens; DBS, deep-brain stimulation; BNST, bed nucleus of the stria
terminalis.
The procedure is safe, effective and reversible, as
well as having received US Food and Drug Admin-
istration (FDA) approvals for essential tremor since
1997 [9]. A Humanitarian Device Exemption was
granted by theUSFDA forDBS for dystonia in 2003
and obsessive-compulsive disorder (OCD) in 2009
[9–11]. To date, there has been mixed evidence
on the efficacy of DBS for major depression, which
has been attributed to patient heterogeneity, inter-
individual variability and trial design [12]. More re-
cently, several studies have also explored the efficacy
and safety of DBS treatment for addiction, which we
review in detail later.
Initially, we discuss ablative surgery, which has
also been applied to addiction treatment. However,
in contrast to DBS, ablative surgery is irreversible
and its application to addictive disorders has pro-
voked most debate and controversy. As an example,
we focus on the rise and fall of nucleus accumbens
(NAc) ablative surgery for opiate addiction inChina
since the early 2000s. We then review recent stud-
ies examining the utility of DBS in treating addiction
(Fig. 2). Subsequently, we discuss several key issues
involved in this clinical field, along with identifying
some areas of progress.
ABLATIVE SURGERY FOR ADDICTION
Since the 1920s, animal studies have disclosed an
intimate structural and functional relationship be-
tween the frontal lobes and the limbic system, par-
ticularly in emotional states of fear, rage, sexual ex-
citement, aggression and pleasure [13]. In primates,
‘loss of fear’ or ‘social indifference’ emerged fol-
lowing bilateral removal of the anterior cingulate
gyrus [14]. Subsequently, based on the assumption
that lesioning cingulate fibers might benefit men-
tally ill persons, cingulotomy (surgical disruption of
the anatomical continuity of the cingulate gyrus)
[15] was used for the treatment of various psy-
chiatric illnesses, including mood disorders, anxi-
ety disorders and OCD.This initial ablative-therapy
study, however, yielded variable results [13,16,17].
One factor that probably has contributed to the
mixed results is related to technical aspects of the
neurosurgical procedure used. Although the neu-
rosurgical procedure used targeted the cingulum
bundle, it is now known that this procedure is not
always precise and can also impact the adjacent
cortex, which might be linked to the therapeutic
effect [18,19].
In 1962, Foltz et al. reported the clinical out-
comes of 16 patients with chronic intractable pain
treated with bilateral (11/16) and unilateral (5/16)
stereotactic anterior cingulum lesions. Interestingly,
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14 patients who were also addicted to narcotics no
longer required the drugs 72 hours after operation
[16,20]. In the 1970s, based on evidence from an-
imal studies and clinical observations, stereotactic
lesions to the ventromedial hypothalamic nucleus
(VMH)were also applied in the neurosurgical treat-
ment of drug addiction [21]. One case of intractable
drug and alcohol addiction was included in Müller’s
series of hypothalamic psychosurgery. A 30-year-
old man with heavy alcohol and drug intake under-
went unilateral hypothalamotomy. Despite promis-
ing early effects on his addiction and lack of adverse
effects, he had to be committed to a psychiatric hos-
pital 10 months after the surgery due to a relapse of
alcoholism [21,22]. In 1978, Kanaka and Balasub-
ramaniam analysed the clinical outcomes of 73 pa-
tients treated with cingulotomy (surgical disruption
of the cingulum by mechanical, thermal or electrical
lesions) for drug addiction [23]. After cingulotomy,
the patients’ addictive behaviors were reduced. The
improvementwas particularly striking in patients ad-
dicted to meperidine, morphine or alcohol. The au-
thors noted that the patients also showed normal
psychometric test scores at follow-up, but details
about these psychological measurements were not
provided. The authors claimed that this procedure
is a promising one for the treatment of drug addic-
tion [23]. In the same year, Dieckmann and Schnei-
der reported a 2- to 3-year follow-up of 13 patients
treated with hypothalamotomy for their addiction
to alcohol or drugs [24]. After hypothalamotomy,
nine patientswere able to control their consumption
and the disabling aspects of addiction, such as poor
social adaptation. However, significant side effects
emerged. And the study concluded that bilateral hy-
pothalamotomy is of limited value in the treatment
of addiction [24].
Since 1998, bilateral cingulotomy has been used
as an addiction treatment at the Institute of the Hu-
man Brain in St. Petersburg, Russia, yet with a dis-
appointing lack of scientific documentation on pa-
tient selection, methods and clinical outcomes. The
procedure involved cryosurgical lesion of the bi-
lateral boundary between the anterior and middle
thirds of the cingulate gyrus, which corresponds to
Brodmann’s area 24.Thiswas accomplished through
small perforations of the skull using stereotactic
techniques [25,26]. In 2002, the surgical procedure
was halted by the Russian authorities after a former
patient complained of adverse side effects and won
a court case against the institute. The patient also
claimed that the operation had failed to improve his
heroin addiction [26,27]. Although a subsequent re-
port from the institute [25] appeared to suggest that
bilateral cingulotomy could be effective in some ad-
dicted patients, the Russian authorities halted the
surgical procedure because it was considered exper-
imental in nature and had not been licensed by the
health ministry.
In conclusion, these early ablative-therapy stud-
ies provide putative evidence that cingulumotomy,
but not hypothalamotomy, could be an effective
and tolerable treatment for some addicted patients.
However, this conclusion should be questioned be-
cause the availability of clinical data is scarce. Well-
controlled clinical trials are required to evaluate
the utility and role of ablative surgery in addiction
treatment.
ABLATIVE SURGERY FOR DRUG
ADDICTION IN CHINA
Early days
In 2000, a hospital in Xi’an launched the first NAc
ablative surgery for treating drug addiction in China
[28].The treatment offered was based on preclinical
studies using a conditioned place-preference model
of drug-seeking behavior in rats and rhesusmonkeys
[28–30]. The results demonstrated that electrolytic
lesions of the NAc markedly decreased morphine-
seeking behavior. The researchers postulated that
the NAc, as compared to other basal ganglia nu-
clei, is the most important component of the brain’s
mesolimbic system involved in drug reinforcement
and addiction. Based on the preclinical results, the
authors claimed thatNAc ablation could be an effec-
tive neurosurgical treatment option for opiate addic-
tion in humans [28].
In 2003, Gao et al. reported the clinical out-
comes of 28 patients treated with NAc ablation for
opiate addiction [31]. After NAc ablation, the pa-
tient outcomes were encouraging, showing relapse
rates of 8% (within 1 month), 39% (between 1 and
6 months) and 58% (after more than 6 months).
As for the reported side effects, four patients experi-
enced temporary memory loss and two patients had
personality changes. However, these side effects ap-
parently did not affect the patients’ daily functioning
or intellectual ability [31].
Ablative surgery becomes popular in
China and issues emerge
The study of Gao et al. published in 2003 at-
tracted wide attention in the neurosurgery field.The
reported clinical benefits of NAc ablation to the
opiate-addicted patients were generally modest and
progressively diminished over the follow-ups. The
results of NAc ablative surgery in treating addiction
still encouraged theneurosurgeons inpsychosurgery
and brought hope for patients who suffered from
intractable drug addiction. However, some private
hospitals driven by financial interests used this
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procedure as a medical service mostly for economic
profit. Conceivably, some patients believed that, fi-
nally and fortunately, an effective, easy, novel treat-
ment for drug addiction was available. Ablative
surgery became rapidly and widely adopted as a
suitable treatment approach to opiate addiction in
China between 2003 and 2004, despite the lack of
solid clinical data. In December 2004, at least 1000
registered patients had received ablative surgery for
opiate addiction [28,32].
Very shortly, several patients reported suffer-
ing from severe side effects after the surgical treat-
ment, which attracted extensivemedia and public at-
tention [33]. For example, journalists from China
Central Television interviewed 50 patients who had
receivedNAc ablative surgery in a specialized hospi-
tal in Guangdong province in November 2004. The
patients were interviewed between 2 and 8 months
after their ablative surgery. Six patients had expe-
rienced a relapse, but the other 44 patients were
still abstinent. However, 26 of the 44 abstinent pa-
tients developed various significant adverse effects.
It should be emphasized, however, that 42 out of the
44 abstinent patients had also used naltrexone as an
adjuvant therapy after their surgery. This makes it
difficult to infer whether the clinical improvements
and side effects seen in these patients weremediated
by the ablative therapy, the adjuvant therapy or by
both treatments combined [33].
Moratorium declared on ablative surgery
The rapid and widespread adoption of NAc ablative
surgery for drug addiction sparked widespread de-
bate and controversy in China. Many medical ex-
perts questioned the effectiveness and safety of the
neurosurgical procedure.The further controversy in-
volved the issue of whether patients should pay for
experimental surgery. In November 2004, China’s
Ministry of Health published the results of the Sym-
posium on Clinical Research on Clinical Detoxifi-
cation of the Ministry of Health, conveying three
important points. First, NAc ablative surgery for
addiction was halted as a medical service. Second,
neurosurgical treatment (including NAc ablative
surgery) for addiction was considered a potentially
promisingmeans topreventdrug relapse,warranting
appropriate clinical studies on efficacy and safety un-
der strict management and supervision. Third, clin-
ical studies on the long-term outcomes of patients
who had received NAc ablative surgery were re-
quired [34].
Lessons to be learned
This historical perspective highlights that experi-
mental ablative surgery for addictionwas too rapidly
incorporated into routine clinical care in China.The
most important things that we should ascertain are
the reasons for the widespread rise and fall of ab-
lative surgery for addiction. First, from a scientific
point of view, well-controlled clinical trials had not
been conducted to support the claim that NAc ab-
lative surgery was a safe and effective treatment for
drug addiction in humans [35–37]. Thus, there ex-
isted no solid scientific basis for its widespread clin-
ical use. Meanwhile, China had a large population
of drug abusers (i.e. the cumulative number of reg-
istered drug users in China increased to 1.05 mil-
lion in 2003) [38] and they lacked effective mea-
sures to curb drug relapse. This represented a huge
market for ablative surgery in treating drug addic-
tion. Often driven by financial interests, some indi-
viduals andprivate hospitals increased their advertis-
ing and directly performed NAc ablative surgery as
a medical service for addicts. Some private hospitals
even performed the experimental surgery without
enough expertise in stereotactic procedures. These
medical malpractices inevitably damaged some pa-
tients’ health, while also restricting the development
of psychosurgery in the long run.
From an ethical point of view, ablative surgery
is an irreversible intervention. The neurosurgeons
can only operate the surgery with patients’ in-
formed consent. Although the surgical procedures
performed in hospitals across China were approved
by their own local ethical committees, the neurosur-
gical treatment for drug addiction had not received
official general approval. Hence, the application of
ablative surgery to addiction treatment in clinical
practice was premature, irresponsible and therefore
halted by China’s Ministry of Health. In China, al-
most every hospital has its own ethics committee
including hospital directors, medical experts and
full-timemanagerial staff. Inpractice, the ethics com-
mittees in some hospitals represent just a formal-
ity. Therefore, it also became clear that the func-
tioning of local hospitals’ ethics committees should
be improved to ensure that basic scientific and ethi-
cal standards are strictly followed in human research
and clinical practice [35,39].
DBS SURGERY FOR ADDICTION
In addition to ablative surgery,DBShas been used to
treat drug addiction. A comprehensive search of the
PubMed database for DBS studies was performed
on 25 March 2019. We consulted the Institute of
Medicine’s Standards for Systematic Reviews, as
well as the PRISMAGroup guidelines [40,41] in es-
tablishing the study-eligibility criteria. First, we con-
ducted a search using the Medical Subject Head-
ing (MeSH) Terms ‘deep brain stimulation’ and
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‘addiction, substance’, which yielded 87 search re-
sults. Next, this number was reduced to 58 after ap-
plying the following three study-eligibility criteria:
the study involved human subjects, the study results
were published between 1 January 1987 through
1 March 2019 and the study report was written in
English or Chinese language. Only clinical studies of
patients with psychiatric and/or substance-use dis-
orders were of interest for this review. Studies were
eliminated that involved patients with neurologic
disorders (e.g. Parkinson’s disease) or employed
clinical-outcome measures other than a substance-
use-related outcome. The reference lists of eligible
study papers were reviewed to identify additional el-
igible papers. Finally, the total number of eligible pa-
pers identified by the stepwise search process was 17
(Table 1). The included DBS-treatment studies fo-
cused on alcohol (n = 7), tobacco smoking (n =
2), heroin (n = 5), cocaine (n = 1) and metham-
phetamine (MA) (n= 2).
Clinical findings
Alcohol
Kuhn et al. observed that a patient consumed re-
markably less alcohol while being treated with NAc
DBS for refractory agoraphobia with panic attacks
alongwith depression [42].His anxiety disorder and
depression, however, were little or not affected fol-
lowing the neurosurgical treatment. A pilot study
of Müller et al. substantiated this initial clinical ob-
servation [43]. Additionally, Kuhn et al. described
a 69-year-old male patient with chronic alcohol
abuse who stopped drinking alcohol all together af-
ter 1 year of bilateral NAc DBS [44]. Subsequently,
Müller et al. reported the long-term (up to 8 years’)
outcomes of five patients treated with NAc DBS
for alcohol addiction. During treatment, two pa-
tients remained abstinent for more than 7 years,
while three patients substantially reduced their al-
cohol consumption [45]. Also, Voges et al. reported
that five alcohol-addicted patients were successfully
treated (average follow-up 38 months) with NAc
DBS [46]. Additionally, De Ridder et al. presented
data from two patients indicating that the anterior
cingulate cortex could also be an effective DBS tar-
get in treatment for alcohol addiction [47,48].
Tobacco smoking
A decade ago, Kuhn et al. described 10 patients
who received NAc DBS treatment for Tourette’s
syndrome, OCD or an anxiety disorder [49]. All
patients were also tobacco smokers before treat-
ment. During 1-, 2- and 2.5-year follow-ups, the re-
searchers incidentally observed a higher rate of suc-
cessful smoking cessation among the patients (20%,
30%and30%)when compared to their reported rate
of unaided smoking cessation in the general pop-
ulation (13%, 19% and 9%) [49]. Similarly, Man-
tione et al. incidentally observed the possible effec-
tiveness of NAcDBS inmodifying tobacco-smoking
behavior [50].
Heroin
To our knowledge, Zhou et al. were the first to de-
scribe a 24-year-oldmale patient treated successfully
with NAc DBS for heroin addiction. In the 6-year
follow-up, the patient remained relapse-free, as con-
firmed by laboratory tests, as well as displaying im-
proved cognitive function and reduced co-morbid
symptoms of anxiety and depression. Immediately
after surgery, the patient experienced mild confu-
sion and urine incontinence, which resolved within
12 hours. No other significant side effects or compli-
cations were reported [51].
Valencia-Alfonso et al. similarly described a
heroin-addicted male patient treated successfully
with DBS of the NAc and adjacent internal capsule.
AfterDBS surgery, the patient’s heroin use and crav-
ing decreased progressively over the first 4 months
of treatment. Subsequently, he was able to stop us-
ing heroin all together. At the final follow-up, the pa-
tient was drug-free for more than 6 months, except
for a 14-day relapse [52].
In line with these case reports, Kuhn et al. re-
ported that NAc DBS was effective in treating two
patients who were chronic users of heroin as well as
of other addictive drugs. After treatment, both pa-
tients showed also reduced levels of anxiety and de-
pression [53]. Furthermore, Chen et al. described
the outcomes of eight patients who had received
DBS of the NAc and anterior limb of the internal
capsule for addiction to heroin and other drugs [54].
With chronic DBS, five patients were abstinent for
more than 3 years, two relapsed after abstinence for
6months and one was lost to follow-up.The authors
reported the occurrence of adverse events, including
an intracranial hemorrhage (<3 ml) adjacent to the
implanted electrode in one patient and a slightmem-
ory decline during chronic stimulation in another
patient.
Cocaine
Goncalves-Ferreira et al. [55] described a patient
whowas treatedwithDBSof theNAc and the neigh-
boring bed nucleus of the stria terminalis for cocaine
addiction. Six months after continuous DBS, the pa-
tient’s cocaine intake and craving were markedly
reduced. Two years after DBS, the clinical bene-
fits were still evident, yet they were smaller than
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Table 1. Chronological listing of DBS treatment for addiction studies included in the review
Studies n Participants
Follow-up
period DBS targets
DBS
parameters Clinical effects Adverse effects
Kuhn et al.
(2007) [42]
1 Alcohol-dependent;
intractable agoraphobia
1 year Bilateral NAc 90μs, 130 Hz,
3–4.5 V
Reduction of alcohol use No side effects
Müller et al.
(2009) [43]
3 Alcohol-dependent 1 year Bilateral NAc 90μs, 130 Hz,
3.5/4.5 V
Two participants
maintained abstinence,
while the other relapsed
Hypomania
Kuhn et al.
(2011) [44]
1 Alcohol-dependent 1 year Bilateral NAc 120μs, 130 Hz,
5.5 V
Reduction in alcohol use NS
Müller et al.
(2016) [45]
5 Alcohol-dependent 4–8 years Bilateral NAc 90μs, 130 Hz,
3.5/4.5 V
Two patients maintained
abstinence for>7 years and
the others relapsed
Hypomania
Voges et al.
(2013) [46]
5 Alcohol-dependent 31–47 months Bilateral NAc 90μs, 130 Hz,
4.5 V
Two participants
maintained abstinence for
>4 years, one showed a
reduction in alcohol use
and two relapsed
Hypomania
De Ridder et al.
(2016) [47]
1 Alcohol-dependent 18 months Bilateral dorsal
anterior cingu-
late/supplementary
motor area
1000μs, 3 Hz,
1.5 mA
The participant maintained
abstinence for>18 months
NS
De Ridder et al.
(2017) [48]
1 Alcohol-dependent;
refractory OCD;
anxiety; depression
9 months Bilateral dorsal
anterior cingulate
cortex
3-Hz burst
mode
Modest reduction in
alcohol use
NS
Kuhn et al.
(2009) [49]
10 Smokers with refractory
Tourette’s syndrome,
OCD or anxiety
disorders
30 months Unilateral/bilateral
NAc
90/180μs,
130/140/
145 Hz,
3–6.5 V
A higher rate of successful
smoking cessation than
general population
NS
Mantione et al.
(2010) [50]
1 Smokers with refractory
OCD and obesity
2 years Bilateral NAc 90μs, 185 Hz,
3.5 V
The participant lost weight
and stopped smoking
NS
Zhou et al.
(2011) [51]
1 Heroin-dependent 6 years Bilateral NAc 90μs, 145 Hz,
0.8–2.5 V
The participant stopped
drug abuse completely
Mild confusion; urine
incontinence
Valencia-
Alfonso et al.
(2012) [52]
1 Heroin-dependent 6 months Bilateral borders of
the internal capsule
and nucleus
accumbens
90μs, 180 Hz,
3.5 V
The participant remained
drug-free for>6 months
(except for one relapse)
NS
Kuhn et al.
(2014) [53]
2 Heroin-dependent;
various drug abuse
1/2 years Bilateral NAc 90/120μs,
130/140 Hz,
4.5/5.0 V
Patients remained off
heroin (except for one
relapse)
Epileptic seizure
Chen et al.
(2018) [54]
8 Heroin-dependent 2 years Bilateral NAc and
the neighboring
anterior limb of the
internal capsule
150–240μs,
130–185 Hz,
1.5–7.0 V
Five participants remained
abstinent for>3 years and
two relapsed
Intracranial
hemorrhage; memory
decline; dizziness;
agitation/irritability;
sweating; difficulty in
falling asleep
Zhang et al.
(2018) [60]
1 Heroin-dependent;
hepatitis C; syphilis;
antisocial personality
disorder
3 months Bilateral ventral
capsule/ventral
striatum
90μs, 130 Hz,
2.5–5.5 V
The participant died from a
heroin overdose
/
Goncalves-
Ferreira et al.
(2016) [55]
1 Cocaine-dependent;
various drug abuse
2.5 years Bilateral
posterior-medial
part of NAc and
neighboring
BNSTs
150μs,
130/150 Hz,
2.0–4.0 V
Reduction in cocaine use Warmness; sweating;
flushing; occasional
metallic taste; transient
weight gain; diminished
libido
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Table 1. (Continued)
Studies n Participants
Follow-up
period DBS targets
DBS
parameters Clinical effects Adverse effects
Zhang et al.
(2019) [56]
1 MA-dependent 1 year Bilateral NAc and
ventral capsule
90μs, 130 Hz,
2.5 V
The participant remained
drug-free and his social
functions were improved
No side effects
Ge et al. (2019)
[57]
2 MA-dependent 1.5/2.5 years Bilateral NAc and
the neighboring
anterior limb of the
internal capsule
210/240μs,
150/165 Hz,
2.5/3.3 V
One participant remained
abstinent, while the other
relapsed
Insomnia; teeth
grinding; hypomania
DBS, deep-brain stimulation; OCD, obsessive-compulsive disorder; STN, subthalamic nucleus; MA, methamphetamine; NAc, nucleus accumbens; NS, not specified.
observed at 6-month follow-up. Side effects of the
treatment were not lasting and rapidly resolved by
adjusting the DBS parameters.
MA
Zhang et al. described a patient with a 5-year history
of intractable MA-use disorder who presented with
noother co-morbid psychiatric or substance-use dis-
orders [56]. During the 1 year of DBS of the NAc
and ventral capsule, the patient remained drug-free
and his social functioning greatly improved. No sig-
nificant side effects were reported. Interestingly, the
patient also underwent positron emission tomogra-
phy (PET-CT) and displayed a marked increase in
striatal DAT density at the 1-year follow-up (20.5%
increase in the caudate, 25.6% increase in the puta-
men relative to 3.2% change in the frontal cortex),
paralleling the clinical benefits of theDBS treatment
[56]. Additionally, Ge et al. reported on the out-
comes of two cases of MA addiction treated with
bilateral NAc DBS [57]. During the approximately
2-year follow-up period, one patient remained MA-
abstinent and reported experiencing more pleasant
emotions. By comparison, the other patient showed
no clinical response to NAc DBS and subsequently
relapsed. According to the authors, a plausible expla-
nation for the discrepancy between the two patients’
clinical outcomes could be related to the spatial ac-
curacy and location stability of the implanted DBS
electrodes. Treatment side effects reported included
insomnia, teeth grinding and a hypomanic period for
less than 1 week, which remitted after adaptation of
the stimulation parameters [57].
The above clinical data suggest that DBS could
have a valuable role to play in the clinical manage-
ment of patients addicted to various psychoactive
substances, including alcohol, tobacco smoking, opi-
ates, cocaine and MA. Also, DBS has been found to
reduce impulsive and compulsive behaviors, includ-
ing abuse of dopaminergic medications and patho-
logical gambling, associatedwithParkinson’s disease
[58,59]. However, the currently available data on
DBS treatment for addiction are extremely limited
and the evidence has come primarily from case re-
ports and case series and shows uneven results, with
several subjects reducing and a minority even stop-
ping their addictive behaviors (for details of DBS-
treatment effects on all the 39 patients, see Supple-
mentary Materials). Meanwhile, various side effects
of DBS addiction treatment have been documented,
such as dizziness, agitation and insomnia, but the
side effects reported are usually transient, not severe
and remitted by adjusting the stimulation parame-
ters. It has been noted that amale patient with a long
history of drug abuse died from aheroin overdose af-
ter 3 months of NAc DBS treatment [60]. It is un-
known, however, whether the fatal outcome of this
patient bears any direct relation to the DBS treat-
ment that he received.
FUTURE DIRECTIONS IN DBS
TREATMENT FOR ADDICTION
Several areas of progress in DBS treatment for ad-
diction may be identified. First, as alluded to earlier,
randomized–controlled studies are urgently needed
to evaluate the efficacy and safety of DBS treatment
for addiction. Also, uncertainty still exists about
the best target and stimulation parameters for DBS
addiction treatment. Although the NAc seems to
be one of the most relevant and widely used tar-
gets, DBS of the NAc combined with the ventral
internal capsule or DBS of other mechanistically
informed targets, such as the subthalamic nucleus,
lateral habenula, medial forebrain bundle or bed nu-
cleus of the stria terminalis, could also be valuable
targets (Fig. 3). In fact, even with the use of NAc
or ventral internal capsule targets, it remains un-
clear which white-matter bundles (e.g. dopaminer-
gic medial forebrain bundle, dorsal versus ventral
anterior thalamic tracts or amygdalofugal) are asso-
ciated with the greatest clinical benefits to the pa-
tients. In addition, it is unknown whether different
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Anterior cingulate cortex (ACC)
Ablative surgery: 
Foltz et al. (1962) [20]
Kanaka et al. (1978) [23]
Medvedev et al. (2003) [25]
DBS surgery:
De Ridder et al. (2016) [47]
De Ridder et al. (2017) [48]
Ablative surgery:
Muller et al. (1973) [22]
Dieckmann et al. (1978) [24]
Ventromedial hypothalamus 
(VMH) 
Subthalamic nucleus 
(STN)
DBS surgery:
Witjas et al. (2005) [58]
Ardouin et al. (2006) [59]
Ablative surgery:
Gao et al. (2003) [31]
Li et al. (2013) [32]
DBS surgery:
Kuhn et al. (2007) [42]
Kuhn et al. (2009) [49]
Muller et al. (2009) [43]
Mantione et al. (2010) [50]
Kuhn et al. (2011) [44]
Zhou et al. (2011) [51]
Voges et al. (2013) [46]
Kuhn et al. (2014) [53]
Muller et al. (2016) [45]
Nucleus accumbens (NAc)
DBS surgery:
Valencia-Alfonso et al. (2012) [52]
Chen et al. (2018) [54]
Zhang et al. (2018) [60]
Zhang et al. (2019) [56]
Ge et al. (2019) [57]
Nucleus accumbens and ventral 
part of the anterior limb of internal 
capsule (NAc and ALIC)
Nucleus accumbens and bed 
mucleus of the stria terminalis
(NAc and BNST)
DBS surgery:
Goncalves-Ferreir et al. (2016) [55]
Figure 3.DBS and ablative-surgery targets in themanagement of addiction. The targets that have been used for neurosurgical
treatment for addiction mainly include: ACC, NAc, STN, NAc and the neighboring ALIC, NAc and the neighboring BNST, and
VMH. Among them, the ACC and NAc targets have been both used for DBS and ablative surgery. The STN, NAc and the
neighboring ALIC, NAc and the neighboring BNST targets were only used for DBS surgery.
targets and stimulation parameters may be more ef-
fective for patientswho are addicted to a certain kind
of substance.
DBS seems to be effective for some, but not all,
addicts. The bases of these inter-individual differ-
ences in clinical response and outcome remain to be
elucidated. Consequently, studies are needed to ex-
amine the potential role of demographics (e.g. age,
gender, socio-economic status, ethnicity) and clini-
cal features (e.g. ageof onset of druguse, severity and
chronicity of drug use, multiple substance use, co-
morbid psychiatric disorders, family history of psy-
chiatric and/or substance-use disorders) in modi-
fying patient outcomes. Also, whether the patient
has a supporting social network available could also
play a significant role in the recovery. The problem
of clinical heterogeneity, however, is related to or
compounded by the likelihood that patients also dif-
fer from each other in terms of etiology—that is,
in the specific genetic [61], epigenetic [62] and en-
vironmental risk factors [63–65] that are involved
in their addictive behaviors. Finally, neuroanatomic
differences between individual patients, affecting the
organization of fiber tracts, are possibly another
source of patient-efficacy variability. It seems, there-
fore, that patients clinically diagnosed with a certain
substance-use disorder form a genetically, etiolog-
ically and clinically heterogeneous patient popula-
tion, which makes it difficult to produce study re-
sults that are identical or comparable across patients
and studies. Ultimately, an individualized therapeu-
tic strategy based on multimodal approaches is cru-
cial to optimize the efficacy and tolerability of DBS
treatment for addiction.
Non-invasive neuromodulation techniques,
such as repetitive transcranial magnetic stimulation
(rTMS) and transcranial direct current stimula-
tion (tDCS), have also provided clinical data on
their effects on craving, cue reactivity, use and
relapse in addictive disorders, which have been
summarized by a recent review [66]. It is clear
that each neuromodulation technique has prac-
tical advantages and disadvantages. For example,
many brain regions implicated in addiction, such
as the NAc and subthalamic nucleus, cannot be
targeted using tDCS or rTMS. In practice, the
use of multimodal neuromodulation techniques
should be taken into account. One could argue that
non-invasive stimulation therapies like rTMS or
tDCS could be initially attempted and, in case there
is no long-lasting response, DBS could be a last
resort to treat addiction in refractory patients [67].
De Ridder and colleagues applied this approach to
target the dorsal anterior cingulate cortex (dACC)
for rTMS based on functional magnetic resonance
imaging (fMRI) and source-localized resting-state
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electroencephalograph. The rTMS treatment
exerted a short-lasting (6 weeks’) clinically mean-
ingful improvement. For ongoing stimulation, two
‘back-to-back’ paddle electrodes were implanted
bilaterally in the dACC. After DBS, the patient
remained free of alcohol intake and experienced
reduced levels of agoraphobia over the 18-month
follow-up [47]. In addition to fMRI, which has
been used for exploring effective DBS targets [47],
other neuroimaging techniques, such as PET-CT,
have also been used for exploring the mechanism
of DBS treatment for addiction [56]. However,
reproducibility in neuroimaging is hindered by the
fact that neuroimaging data are typically derived
from group-level analyses and may not come true at
the level of an individual [68].The use of supervised
machine learning provides more information on the
whole-brain neural correlates of addictive processes
that may be applied at the individual level. More
importantly, well-controlled prospective studies
are needed to ascertain whether insights from
neuroimaging are able to provide reliable brain
biomarkers for addiction treatment [68].
Given rapid dynamic change related to the key
neurocognitive processes associated with addiction,
high-temporal-resolution signals of human-brain
processing based on electrophysiology, namely
event-related potentials (ERPs) may enrich our
understanding of the neural mechanisms of ad-
diction from a more dynamic and comprehensive
perspective. For instance, Valencia-Alfonso and
colleagues’ work showed us that pretreatment
recordings of the implanted target in response
to symptom triggers can help to determine the
clinically most effective target for DBS stimulation
and facilitate custom-tailored DBS treatment [52].
Meanwhile, a diverse range of ERPs can act as the
index of behavior change in patients with addiction
[69]. However, few of the addictive-behavior-
associated ERPs have been used for monitoring
the therapeutic effect of DBS treatment for
addiction.
A promising new technique towards a person-
oriented approach to DBS treatment is known as
a ‘closed-loop’ DBS system. This technique refers
to a closed-loop feedback control system that can
detect certain biological signals in the brain, such
as beta local field potential levels in patients with
Parkinson’s disease. Subsequently, if therapeutically
required, the system can use the biological signal
of interest to change the DBS-treatment parameters
and thereby titrate the detected signal to a desired
range. Closed-loop DBS has already been approved
by the US FDA for epilepsy treatment [70]. Un-
fortunately, closed-loop DBS is not yet available for
addiction treatment because of the absence of re-
ports on effective and feasible biological signals or
biomarkers that are both sensitive and specific to
the mental and brain state of interest (e.g. craving,
cue- or stress-induced intentions, or impulses to seek
and take drugs) and suitable for clinical use. When
such biomarkers become available, DBS for addic-
tion treatment could become individually tuned and
more focused on the pathophysiological process in-
volved, ultimately making it more clinically effective
[66,71].
CONCLUSION
In the past half-century, neurosurgeons have en-
deavored to find effective and safe operations for the
treatment of addiction. However, due to the lack of
high-level clinical trials and proper scientific under-
standing for these procedures, there is limited evi-
dence in favor of any operation for the treatment of
addiction to date. With the advance of technical ap-
proaches and understanding of neurophysiology, as
well as the accumulation of high-level clinical trials’
data, the surgical treatment for addiction will con-
tinue tomove towards a safer andmore standardized
direction.
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